Skin Conditions

Skin Patch Test Shows Promise in Diagnosis and Prevention of Abacavir Hypersensitivity - 7/01/05

Boehringer Ingelheim Wins FDA Approval to Market Protease Inhibitor Tipranavir (Aptivus) for Treatment of Drug-resistant HIV - 6/24/05

Once-daily Administration of Abacavir Is Not a Clinical Risk Factor for Suspected Hypersensitivity Reactions in Clinical Trials, and Rash Alone Is Not Sufficient to Diagnose the Reaction - 3/18/05

Symptoms and Sites of Pain Experienced by AIDS Patients - 09/17/04

Thalidomide Curbs Refractory Itching in Some HIV Patients - 07/30/04

Skin Discoloration with Emtricitabine (FTC) - 07/28/04

Incidence of Skin Discoloration Across Phase III Clinical Trials of Emtricitabine  - 07/21/04

Risk Factors and Occurrence of Rash in HIV-positive Patients with Low CD4 levels (< 50) Not Receiving NNRTIs 03/29/04

Nevirapine Improves the Efficacy of a Triple Nucleoside Regimen, and the Addition of Hydroxyurea Contributes to Treatment Failure Due to Toxicity 03/24/04

Cetirizine Does Not Reduce the Rate of Nevirapine-related Rash 10/03/03

Data on Lipodystrophy and Adverse Drug Reactions at the 43rd ICAAC - 09/19/03

Rash Update from the 5th Workshop on Adverse Drug Reactions and Lipodystrophy in HIV 07/09/03

Prednisone Does Not Decrease Risk of Viramune (nevirapine) Rash - 05/14/03
 

HIV AND AIDS | HEPATITIS B | HEPATITIS C | HIV / HBV CO-INFECTION | HIV / HCV CO-INFECTION | HEALTH AND TECHNOLOGY | TESTS | INTERNET CONFERENCE REPORTS | TELECONFERENCES | LINKS | ABOUT US | CONTACT US